title: Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis.
abstract: Long-term immunoprophylaxis with anti-HBs immunoglobulins (HBIg) is used to prevent hepatitis B (HBV) reinfection after liver transplantation for HBV-related cirrhosis. This approach is highly expensive. A recent report proposed posttransplant HBV vaccination with a reinforced schedule as an alternative strategy to allow HBIg discontinuation. We investigated the efficacy of a reinforced triple course of HBV vaccination in 17 patients transplanted for HBsAg-positive cirrhosis 2 to 7 years earlier. The first cycle consisted of 3 double intramuscular doses (40 microg) of recombinant vaccine at month 0, 1, and 2, respectively. This was followed, in nonresponders, by a second cycle of 6 intradermal 10 microg doses every 15 days. All nonresponders then received a third cycle identical to the first one. Vaccination started 4.5 months after HBIg discontinuation, and lamivudine (100 mg/day) was given throughout the study. All patients were seronegative for HBsAg and HBV-DNA (by PCR) and positive for anti-HBe, and 7 were positive for anti-HDV. After the first cycle one patient (#5, 53 years old, male) developed an anti-HBs titer of 154 IU/L, another (#12) reached a titer of 20 IU/L and the remainder had titers <10 IU/L. At month 7, patient #5 reached a titer of 687 IU/L. After the second cycle only one additional patient (#9) had a slight response (an anti-HBs titer of 37 IU/L). After the third cycle patient #9 rose to an anti-HBs titer of 280 IU/L, patient #12 dropped to 10 IU/L, and no other patient responded. In conclusion, a highly reinforced HBV vaccination program is effective only in a few patients who had liver transplants for HBV-related cirrhosis.
authors.affiliation: Gastroenterology Unit, Department of Public Health, and Liver Transplantation Center, Department of Surgery, University of Rome Tor Vergata, Medical School, Rome, Italy. angelico@med.uniroma2.it
authors.forename: Mario
authors.initials: M
authors.lastname: Angelico
authors.forename: Daniele
authors.initials: D
authors.lastname: Di Paolo
authors.forename: Massimo O
authors.initials: MO
authors.lastname: Trinito
authors.forename: Alessandra
authors.initials: A
authors.lastname: Petrolati
authors.forename: Antonio
authors.initials: A
authors.lastname: Araco
authors.forename: Settimio
authors.initials: S
authors.lastname: Zazza
authors.forename: Raffaella
authors.initials: R
authors.lastname: Lionetti
authors.forename: Carlo U
authors.initials: CU
authors.lastname: Casciani
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Tisone
mesh_terms: D000328:Adult; D004279:DNA, Viral / Q000097:blood; D005260:Female; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D017325:Hepatitis B Vaccines / Q000008:administration & dosage*; D006513:Hepatitis B e Antigens / Q000276:immunology; D006515:Hepatitis B virus / Q000235:genetics / Q000276:immunology; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use; D019259:Lamivudine / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000601:surgery* / Q000821:virology*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D017211:Treatment Failure; D014614:Vaccines, Synthetic / Q000008:administration & dosage
chemical_list: D004279:DNA, Viral; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D006513:Hepatitis B e Antigens; D007136:Immunoglobulins; D014614:Vaccines, Synthetic; D019259:Lamivudine; C045213:hepatitis B hyperimmune globulin